Published in Br J Haematol on December 01, 1997
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood (2013) 2.97
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw (2011) 1.85
Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp Hematol (2007) 1.24
Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome. Blood (2006) 1.18
Myelodysplastic syndromes: clinical practice guidelines in oncology. J Natl Compr Canc Netw (2013) 1.12
Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia. Haematologica (2011) 1.07
Current therapy of myelodysplastic syndromes. Blood Rev (2013) 1.07
Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome. Leukemia (2009) 1.06
New drugs in the treatment of myelodysplastic syndromes: are they changing the role of transfusion support? Blood Transfus (2008) 1.00
Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform. Eur J Clin Invest (2008) 0.98
Managing myelodysplastic symptoms in elderly patients. Clin Interv Aging (2009) 0.92
Immunological derangement in hypocellular myelodysplastic syndromes. Transl Med UniSa (2014) 0.89
Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment. Blood (2009) 0.87
Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study. Br J Haematol (2010) 0.87
Cytogenetic profile of aplastic anaemia in Indian children. Indian J Med Res (2013) 0.85
T-cell receptor Vβ skewing frequently occurs in refractory cytopenia of childhood and is associated with an expansion of effector cytotoxic T cells: a prospective study by EWOG-MDS. Blood Cancer J (2014) 0.82
Immune dysregulation in myelodysplastic syndrome. Hematol Rep (2010) 0.82
How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program (2010) 0.81
A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction. Haematologica (2014) 0.81
Immunosuppressive therapy for myelodysplastic syndrome: efficacy of methylprednisolone pulse therapy with or without cyclosporin A. J Cancer Res Clin Oncol (2003) 0.79
Abnormalities of the alphabeta T-cell receptor repertoire in advanced myelodysplastic syndrome. Exp Hematol (2009) 0.79
[Individualized management and therapy of myelodysplastic syndromes]. Wien Klin Wochenschr (2008) 0.78
Immune Mechanisms in Myelodysplastic Syndrome. Int J Mol Sci (2016) 0.78
Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab. Semin Hematol (2012) 0.77
Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS). Wien Klin Wochenschr (2003) 0.77
The role of magnetic resonance imaging in the evaluation of transfusional iron overload in myelodysplastic syndromes. Rev Bras Hematol Hemoter (2015) 0.75
Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta (1986) 13.69
A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures. Connect Tissue Res (1982) 7.12
Cathepsin B, Cathepsin H, and cathepsin L. Methods Enzymol (1981) 6.84
The interaction of alpha 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. Biochem J (1973) 5.99
Evolutionary families of peptidases. Biochem J (1993) 5.81
L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem J (1982) 5.67
Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med (2000) 4.99
Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med (1994) 4.86
Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science (1993) 4.12
Human cathepsin B1. Purification and some properties of the enzyme. Biochem J (1973) 4.06
The electrophoretically 'slow' and 'fast' forms of the alpha 2-macroglobulin molecule. Biochem J (1979) 3.58
Evolutionary families of metallopeptidases. Methods Enzymol (1995) 3.48
5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. N Engl J Med (1982) 3.29
A rapid and reproducible assay for collagenase using [1-14C]acetylated collagen. Anal Biochem (1979) 3.17
Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I). Am J Hum Genet (1990) 3.10
Cathepsin D. Purification of isoenzymes from human and chicken liver. Biochem J (1970) 3.09
A human parvovirus-like virus inhibits haematopoietic colony formation in vitro. Nature (1983) 3.02
Families of serine peptidases. Methods Enzymol (1994) 2.94
Chronic bone marrow failure due to persistent B19 parvovirus infection. N Engl J Med (1987) 2.93
A new assay for cathepsin B1 and other thiol proteinases. Anal Biochem (1972) 2.93
Gram-negative sepsis: detection of endotoxemia with the limulus test. With studies of associated changes in blood coagulation, serum lipids, and complement. Ann Intern Med (1972) 2.79
Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med (2001) 2.75
High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet (2000) 2.75
Cathepsin B1. A lysosomal enzyme that degrades native collagen. Biochem J (1974) 2.65
An invertebrate coagulation system activated by endotoxin: evidence for enzymatic mediation. J Clin Invest (1972) 2.61
Cathepsin D. Characteristics of immunoinhibition and the confirmation of a role in cartilage breakdown. Biochem J (1971) 2.60
MEROPS: the peptidase database. Nucleic Acids Res (1999) 2.60
Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions. Proc Natl Acad Sci U S A (1991) 2.55
Cyclosporin A for the treatment of graft-versus-host disease in man. Lancet (1979) 2.48
An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation. Nature (1998) 2.44
Cystatin, a protein inhibitor of cysteine proteinases. Improved purification from egg white, characterization, and detection in chicken serum. Biochem J (1983) 2.42
Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood (2000) 2.42
Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. Proc Natl Acad Sci U S A (1985) 2.33
Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3. Virology (1996) 2.26
Pectic polysaccharides of growing plant tissues. Biochem J (1967) 2.24
Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet (1981) 2.22
Fluorimetric assays for cathepsin B and cathepsin H with methylcoumarylamide substrates. Biochem J (1980) 2.20
Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med (1999) 2.17
Neutral proteinases of human spleen. Purification and criteria for homogeneity of elastase and cathepsin G. Biochem J (1976) 2.17
Human liver cathepsin L. Biochem J (1985) 2.16
A study of cancer, parity and age at first pregnancy. J Chronic Dis (1980) 2.13
Lysosomal acid proteinase of rabbit liver. Biochem J (1967) 2.12
The interaction of alpha2-macroglobulin with proteinases. Binding and inhibition of mammalian collagenases and other metal proteinases. Biochem J (1974) 2.11
Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood (2001) 2.11
Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest (1989) 2.08
The inhibition of tissue acid proteinases by pepstatin. Biochem J (1972) 2.06
Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol (2002) 2.05
Isolation of six cysteine proteinase inhibitors from human urine. Their physicochemical and enzyme kinetic properties and concentrations in biological fluids. J Biol Chem (1986) 2.03
CA074 methyl ester: a proinhibitor for intracellular cathepsin B. Arch Biochem Biophys (1992) 2.03
Hepatitis-associated aplastic anemia. N Engl J Med (1997) 1.98
Families of cysteine peptidases. Methods Enzymol (1994) 1.98
Adeno-associated virus type 2 binds to a 150-kilodalton cell membrane glycoprotein. Virology (1996) 1.97
Persistent B19 parvovirus infection as a cause of severe chronic anaemia in children with acute lymphocytic leukaemia. Lancet (1988) 1.97
Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J Virol (1999) 1.97
Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood (1995) 1.91
Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer (2008) 1.90
Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood (2001) 1.89
Hypertension and convulsions in children receiving cyclosporin A. Lancet (1982) 1.89
Human cathepsin H. Biochem J (1980) 1.88
An improved color reagent for use in Barrett's assay of Cathepsin B. Anal Biochem (1976) 1.87
Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med (1989) 1.85
Lymph node metastases in low-grade endometrial stromal sarcoma. Gynecol Oncol (2005) 1.83
Regulated high level expression of a human gamma-globin gene introduced into erythroid cells by an adeno-associated virus vector. Proc Natl Acad Sci U S A (1992) 1.82
Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat (2010) 1.79
Characterization of a virus that causes transient aplastic crisis. J Clin Invest (1984) 1.78
Infection of hematopoietic progenitor cells by human cytomegalovirus. Blood (1992) 1.76
Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol (1993) 1.76
Recombinant adeno-associated virus-mediated gene transfer into hematopoietic progenitor cells. Blood (1994) 1.75
Action of rat liver cathepsin L on collagen and other substrates. Biochem J (1982) 1.73
Nomenclature and classification of the proteins homologous with the cysteine-proteinase inhibitor chicken cystatin. Biochem J (1986) 1.71
Dengue virus, a flavivirus, propagates in human bone marrow progenitors and hematopoietic cell lines. Blood (1989) 1.69
Inhibition of cysteine proteinases and dipeptidyl peptidase I by egg-white cystatin. Biochem J (1984) 1.69
MEROPS: the peptidase database. Nucleic Acids Res (2000) 1.69
Immunologic abnormalities in patients receiving multiple blood transfusions. Ann Intern Med (1984) 1.66
A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med (2006) 1.66
Human cathepsin G. Catalytic and immunological properties. Biochem J (1976) 1.65
Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro. Nat Med (1995) 1.65
The many forms and functions of cellular proteinases. Fed Proc (1980) 1.64
Haematological and biochemical monitoring of Ebola infection in rhesus monkeys: implications for patient management. Lancet (1983) 1.64
Cloning, isolation, and characterization of mammalian legumain, an asparaginyl endopeptidase. J Biol Chem (1997) 1.63
Chicken alpha2-proteinase inhibitor: a serum protein homologous with ovoinhibitor of egg white. Biochim Biophys Acta (1974) 1.63
Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface. J Clin Invest (1992) 1.63
Clinical relevance of parvovirus B19 as a cause of anemia in patients with human immunodeficiency virus infection. J Infect Dis (1997) 1.63
Possible lysosomal activation of pancreatic zymogens. Activation of both human trypsinogens by cathepsin B and spontaneous acid. Activation of human trypsinogen 1. Biol Chem Hoppe Seyler (1988) 1.63
The degradation of cartilage proteoglycans by tissue proteinases. Proteoglycan structure and its susceptibility to proteolysis. Biochem J (1977) 1.63
Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood (1997) 1.63
Identification of the probable inhibitory reactive sites of the cysteine proteinase inhibitors human cystatin C and chicken cystatin. J Biol Chem (1987) 1.61
Human lysosomal elastase. Catalytic and immunological properties. Biochem J (1976) 1.59
The degradation of articular collagen by neutrophil proteinases. Biochim Biophys Acta (1977) 1.59
Lysosomes. Essays Biochem (1976) 1.58
Detection of CK-19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes. Ann Oncol (2005) 1.58